Context Therapeutics Future Growth
Future criteria checks 0/6
Context Therapeutics's earnings are forecast to decline at 7.2% per annum while its annual revenue is expected to grow at 77.1% per year. EPS is expected to grow by 3.5% per annum.
Key information
-7.2%
Earnings growth rate
3.5%
EPS growth rate
| Pharmaceuticals earnings growth | 19.8% |
| Revenue growth rate | 77.1% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 15 Jan 2025 |
Recent future growth updates
Recent updates
We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth
Aug 15
We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Mar 27Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely
Sep 28Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?
Jun 05Context to focus on ELONA trial, CLDN6 program, extends cash runway into 1Q24
Sep 27We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Sep 15Context Therapeutics GAAP EPS of -$0.25 in-line
Aug 11Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial
Aug 02Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth
May 28Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential
Nov 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | N/A | -53 | -52 | -34 | 5 |
| 12/31/2026 | N/A | -44 | -42 | -30 | 5 |
| 12/31/2025 | N/A | -34 | -38 | -30 | 6 |
| 12/31/2024 | N/A | -32 | -29 | -16 | 6 |
| 9/30/2024 | N/A | -30 | -32 | -17 | N/A |
| 6/30/2024 | N/A | -19 | -18 | -18 | N/A |
| 3/31/2024 | N/A | -21 | -20 | -20 | N/A |
| 12/31/2023 | N/A | -24 | -21 | -21 | N/A |
| 9/30/2023 | N/A | -21 | -18 | -18 | N/A |
| 6/30/2023 | N/A | -19 | -18 | -17 | N/A |
| 3/31/2023 | N/A | -18 | -16 | -15 | N/A |
| 12/31/2022 | N/A | -15 | -14 | -14 | N/A |
| 9/30/2022 | N/A | -14 | -15 | -15 | N/A |
| 6/30/2022 | N/A | -12 | -12 | -12 | N/A |
| 3/31/2022 | N/A | -13 | -11 | -11 | N/A |
| 12/31/2021 | N/A | -10 | -9 | -9 | N/A |
| 9/30/2021 | N/A | -8 | -4 | -4 | N/A |
| 6/30/2021 | N/A | -7 | -5 | -4 | N/A |
| 3/31/2021 | N/A | -1 | -3 | -3 | N/A |
| 12/31/2020 | N/A | 1 | -1 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CNTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CNTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CNTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CNTX is forecast to have no revenue next year.
High Growth Revenue: CNTX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CNTX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 10:12 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Context Therapeutics Inc. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Soo Romanoff | Edison Investment Research |
| Emily Bodnar | H.C. Wainwright & Co. |